OVERVIEW

The IAS–USA Annual Virtual Course Update: Emerging Challenges in HIV Medicine is organized by International Antiviral Society-USA (IAS-USA) and will be held on Dec 01, 2026.

Description:
This comprehensive half-day virtual course will provide practical updates on emerging challenges in HIV medicine, with a focus on clinical decision-making for people with HIV across the continuum of care. Through expert presentations, interactive case discussions, and panel-based learning, participants will explore evolving approaches to antiretroviral therapy (ART), including regimen simplification, management of drug resistance, investigational therapies, and complex treatment cases.

The course will also address the diagnosis and management of cognitive decline in people with HIV, including the intersection of aging, Alzheimer’s disease, dementia, cytomegalovirus infection, and other neurologic complications. Additional sessions will review new evidence on reducing cardiovascular disease risk in people with HIV, with updates from the REPRIEVE trial and current American Heart Association (AHA) guidelines. Participants will leave with practical strategies for applying the latest evidence to optimize HIV care in clinical practice.

Learning Objectives:
After participating in the activity, learners will be able to:

Implement the latest recommendations for initiating and changing ART in clinical circumstances such as regimen simplification, drug resistance, and newly approved or investigational therapies
Describe emerging investigational ART and potential roles in future HIV treatment
Apply current evidence on HIV drug resistance, including clinically important resistance mutations, to optimize ART
Incorporate recent evidence and guideline updates, including findings from the REPRIEVE trial and current AHA recommendations, to reduce cardiovascular disease risk in people with HIV
Differentiate cognitive decline–related aging from HIV-associated neurologic complications and apply appropriate diagnostic and management strategies.

Preliminary Topics:

Challenging ART cases: regimen simplification, drug resistance, and emerging therapies
Investigational drugs and treatment strategies in the pipeline
HIV drug resistance updates
Cognitive decline in people with HIV: aging and HIV-related neurologic complications
Cardiovascular disease prevention in people with HIV